Affimed to Present at the 26th Annual Credit Suisse Healthcare Conference

Press Release - November 2, 2017

Download Press Release

Heidelberg, Germany, November 2, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the 26th Annual Credit Suisse

Healthcare Conference on Wednesday, November 8, 2017 at 12:10 pm MT in Scottsdale, Arizona. A live webcast of the conference presentation can be accessed through the Webcasts page on our Website. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit


Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required, email hidden; JavaScript is required